Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, Escobar A, Ginesta A, Reyes D, González R, Mendoza-Naranjo A, Larrondo M, Compán A, Ferrada C, Salazar-Onfray F. López MN, et al. Among authors: pereda c. J Clin Oncol. 2009 Feb 20;27(6):945-52. doi: 10.1200/JCO.2008.18.0794. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139436 Clinical Trial.
Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
Tittarelli A, González FE, Pereda C, Mora G, Muñoz L, Saffie C, García T, Díaz D, Falcón C, Hermoso M, López MN, Salazar-Onfray F. Tittarelli A, et al. Among authors: pereda c. Cancer Immunol Immunother. 2012 Nov;61(11):2067-77. doi: 10.1007/s00262-012-1268-7. Epub 2012 May 3. Cancer Immunol Immunother. 2012. PMID: 22552381 Free PMC article.
The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN. Durán-Aniotz C, et al. Among authors: pereda c. Cancer Immunol Immunother. 2013 Apr;62(4):761-72. doi: 10.1007/s00262-012-1377-3. Epub 2012 Dec 15. Cancer Immunol Immunother. 2013. PMID: 23242374 Free PMC article.
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
García-Salum T, Villablanca A, Matthäus F, Tittarelli A, Baeza M, Pereda C, Gleisner MA, González FE, López MN, Hoheisel JD, Norgauer J, Gebicke-Haerter PJ, Salazar-Onfray F. García-Salum T, et al. Among authors: pereda c. Oncotarget. 2018 Mar 30;9(24):17014-17027. doi: 10.18632/oncotarget.24795. eCollection 2018 Mar 30. Oncotarget. 2018. PMID: 29682201 Free PMC article.
Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
Falcón-Beas C, Tittarelli A, Mora-Bau G, Tempio F, Pérez C, Hevia D, Behrens C, Flores I, Falcón-Beas F, Garrido P, Ascui G, Pereda C, González FE, Salazar-Onfray F, López MN. Falcón-Beas C, et al. Among authors: pereda c. Immunobiology. 2019 Sep;224(5):697-705. doi: 10.1016/j.imbio.2019.05.011. Epub 2019 Jun 6. Immunobiology. 2019. PMID: 31221438
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro.
Flores I, Hevia D, Tittarelli A, Soto D, Rojas-Sepúlveda D, Pereda C, Tempio F, Fuentes C, Falcón-Beas C, Gatica J, Falcón-Beas F, Galindo M, Salazar-Onfray F, González FE, López MN. Flores I, et al. Among authors: pereda c. J Immunol Res. 2019 Nov 25;2019:9631515. doi: 10.1155/2019/9631515. eCollection 2019. J Immunol Res. 2019. PMID: 31886313 Free PMC article.
72 results